The recombinant influenza vaccine is a type of vaccine developed using genetic engineering technology, aimed at preventing influenza virus infections. Unlike traditional protein vaccines, recombinant vaccines selectively produce immunogenic antigen proteins by recombining viral gene sequences. This approach not only enhances the safety and stability of the vaccine but also more effectively stimulates the human immune system.
The development background of recombinant influenza vaccines lies in the limitations of traditional vaccine production processes, such as dependence on chicken embryos and lengthy production cycles. The introduction of recombinant technology has made vaccine production more efficient and controllable, which is especially important in addressing the challenges posed by the rapid mutation of influenza viruses.
Recombinant influenza vaccines belong to subunit vaccines, with the core mechanism of inducing the human body to produce antibodies and memory cells targeting specific influenza virus proteins. These antibodies can specifically recognize and neutralize invading viruses, effectively preventing infection.
Unlike whole-virus vaccines, recombinant vaccines contain only parts of the virus, such as hemagglutinin (HA) or neuraminidase (NA), which are surface proteins of the influenza virus and are crucial for viral infection and transmission. By injecting these recombinant proteins, the immune system can establish a specific immune response in advance without being infected by the virus.
Recombinant influenza vaccines are primarily used to prevent seasonal influenza infections, especially during seasons with high viral mutation, providing broader protection. It is suitable for healthy individuals aged 6 months and above, including adults and children.
Additionally, recombinant vaccines are recommended for those who may have allergic reactions to traditional protein vaccines, such as individuals allergic to eggs or other vaccine components. Since their production process does not involve chicken embryos, recombinant vaccines can effectively reduce the risk of allergic reactions.
Recombinant influenza vaccines are usually administered via intramuscular or subcutaneous injection, recommended to be performed by healthcare professionals. The dosage for adults and children is typically 0.5 mL, containing 15 micrograms of hemagglutinin antigen per dose.
According to influenza vaccination guidelines, it is recommended to receive the vaccine once annually to maintain immunity against the latest circulating strains. High-risk groups such as the elderly, young children, pregnant women, and individuals with chronic illnesses should strictly follow vaccination recommendations.
The main advantages of recombinant influenza vaccines are their high efficacy and safety. Compared to traditional vaccines, they can induce an immune response more rapidly and are well tolerated across different age groups.
Like all vaccines, recombinant influenza vaccines may cause mild side effects, usually related to reactions at the injection site. The most common side effects include pain, redness, or swelling at the injection site, which typically resolve within a few days.
In rare cases, allergic reactions such as rashes, vomiting, or difficulty breathing may occur. If these symptoms appear, immediate medical attention should be sought.
Contraindications for recombinant influenza vaccines include allergies to vaccine components and individuals who have experienced severe allergic reactions following previous vaccinations. Pregnant and breastfeeding women should consult their doctor before use to assess risks and benefits.
Furthermore, patients with high fever or acute infections are advised to delay vaccination until their condition stabilizes to ensure optimal immune response.
Research on interactions between recombinant influenza vaccines and other drugs or vaccines is limited. It is recommended to inform the healthcare provider of all medications being used, especially immunosuppressants that may affect immune responses.
When administered simultaneously with other vaccines, follow the doctor’s guidance to ensure effective immune responses.
Clinical trial data demonstrate that recombinant influenza vaccines have significant efficacy in preventing seasonal influenza, especially in reducing severe cases and hospitalizations. Studies show that vaccination with recombinant vaccines can reduce the risk of influenza infection by 40%-60%.
Additionally, recombinant vaccines can provide some cross-protection against viral mutations, making them particularly important during seasons with rapidly mutating influenza viruses.
If patients are unsuitable for recombinant influenza vaccination, doctors may recommend other types of influenza vaccines, such as whole-virus vaccines or subunit vaccines. These vaccines have different indications and efficacy profiles in various populations.
For certain special cases, physicians might also suggest other preventive measures, such as antiviral medications or enhanced personal hygiene practices.
Before receiving the recombinant influenza vaccine, it is advisable to discuss your health condition with your doctor, especially regarding any severe allergies or immune system disorders. On the day of vaccination, maintain normal physical condition, avoid fatigue, and ensure a normal diet. The doctor may recommend observing for a period after vaccination to monitor for any adverse reactions.
What are the side effects of the recombinant influenza vaccine?The recombinant influenza vaccine is generally safe. Most people may experience mild side effects such as redness, pain, or swelling at the injection site, or mild fever and fatigue. These symptoms usually resolve within a few days. In rare cases, severe allergic reactions like difficulty breathing, facial swelling, or throat numbness may occur; immediate medical attention is necessary.
What lifestyle precautions should I take after vaccination?After vaccination, it is recommended to maintain good lifestyle habits, such as adequate sleep, balanced diet, and moderate exercise to boost immunity. Avoid high-risk environments for influenza exposure and practice good personal hygiene, such as frequent handwashing. If any unusual symptoms occur, seek medical attention promptly.
How effective is the recombinant influenza vaccine?The recombinant influenza vaccine generally has high efficacy, significantly reducing the risk of influenza infection and the severity of illness. However, the protective effect may vary depending on individual health, age, and viral mutation. Annual vaccination with the latest vaccine is recommended for optimal protection against the current season’s circulating strains.
How often should I get the recombinant influenza vaccine?It is generally recommended to receive the recombinant influenza vaccine once a year to cope with different influenza strains each year. Based on individual health status and risk factors, more frequent vaccination may be advised, especially for the elderly or immunocompromised individuals, to ensure optimal protection.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
